Skip to main content
    H

    Haemonetics Corporation (HAE)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $121.35
    +0.24 (+0.20%)

    Market Cap: $5.51B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    92%(36/39)
    Avg Surprise
    +11.00%
    Streak
    19 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$1.29
    Range$1.21 - $1.37
    11 analysts
    EPS Revisions
    6
    0
    7d
    6
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$1.28+1.1%
    60d ago$1.27+1.3%
    30d ago$1.29+0.1%
    7d ago$1.290.0%
    Current$1.29
    Revenue Consensus
    $345M
    Range$338M - $355M
    11 analysts
    Period ending Dec 31, 2026
    EPS Consensus$1.36
    Range$1.25 - $1.43
    11 analysts
    EPS Revisions
    3
    0
    7d
    3
    5
    30d
    EPS Estimate DriftChange to current
    90d ago$1.38-1.8%
    60d ago$1.39-2.0%
    30d ago$1.35+0.3%
    7d ago$1.360.0%
    Current$1.36
    Revenue Consensus
    $358M
    Range$351M - $367M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 27EST
    		-$1.58---
    Dec 26EST
    		-$1.36---
    Sep 26EST
    		-$1.29---
    Jun 26
    Reported Aug 6
    		$1.14$1.07+6.54%Beat+3.6%
    Mar 26
    Reported May 7
    		$1.29$1.27+1.57%Beat+4.0%
    Dec 25
    Reported Feb 5
    		$1.31$1.25+4.80%Beat+10.1%
    Sep 25
    Reported Nov 6
    		$1.27$1.11+14.41%Beat+13.4%
    Jun 25
    Reported Aug 7
    		$1.10$1.01+8.91%Beat+7.8%
    Mar 25
    Reported May 8
    		$1.24$1.22+1.64%Beat+37.8%
    Dec 24
    Reported Feb 6
    		$1.19$1.17+1.71%Beat+14.4%
    Sep 24
    Reported Nov 7
    		$1.12$1.07+4.67%Beat+13.1%
    Jun 24
    Reported Aug 8
    		$1.02$1.01+0.99%Beat-2.9%
    Mar 24
    Reported May 9
    		$0.90$0.89+1.12%Beat+16.9%
    Dec 23
    Reported Feb 8
    		$1.04$0.94+10.64%Beat+22.4%
    Sep 23
    Reported Nov 2
    		$0.99$0.89+11.24%Beat+19.3%
    Jun 23
    Reported Aug 8
    		$1.05$0.73+43.84%Beat+81.0%
    Mar 23
    Reported May 11
    		$0.77$0.70+10.00%Beat+18.5%
    Dec 22
    Reported Feb 7
    		$0.85$0.82+3.66%Beat+1.2%
    Sep 22
    Reported Nov 7
    		$0.83$0.67+23.88%Beat+38.3%
    Jun 22
    Reported Aug 10
    		$0.58$0.51+13.73%Beat+16.0%
    Mar 22
    Reported May 10
    		$0.65$0.60+8.33%Beat+41.3%
    Dec 21
    Reported Feb 8
    		$0.84$0.73+15.07%Beat+3.7%
    Sep 21
    Reported Nov 9
    		$0.60$0.61-1.64%Miss-3.2%
    Jun 21
    Reported Aug 11
    		$0.50$0.45+11.11%Beat+8.7%
    Mar 21
    Reported May 13
    		$0.46$0.67-31.34%Miss-33.3%
    Dec 20
    Reported Feb 2
    		$0.81$0.65+24.62%Beat-13.8%
    Sep 20
    Reported Nov 4
    		$0.62$0.51+21.57%Beat-28.7%
    Jun 20
    Reported Aug 4
    		$0.46$0.41+12.20%Beat-43.2%
    Mar 20
    Reported May 5
    		$0.69$0.73-5.48%Miss+13.1%
    Dec 19
    Reported Feb 4
    		$0.94$0.76+23.68%Beat+49.2%
    Sep 19
    Reported Nov 1
    		$0.87$0.72+20.83%Beat+55.4%
    Jun 19
    Reported Aug 6
    		$0.81$0.64+26.56%Beat+37.3%
    Mar 19
    Reported May 7
    		$0.61$0.55+10.91%Beat+41.9%
    Dec 18
    Reported Feb 5
    		$0.63$0.59+6.78%Beat+1.6%
    Sep 18
    Reported Nov 6
    		$0.56$0.54+3.70%Beat+16.7%
    Jun 18
    Reported Aug 7
    		$0.59$0.42+40.48%Beat+78.8%
    Mar 18
    Reported May 8
    		$0.43$0.43+0.00%Beat+10.3%
    Dec 17
    Reported Feb 6
    		$0.62$0.44+40.91%Beat+44.2%
    Sep 17
    Reported Nov 7
    		$0.48$0.41+17.07%Beat-
    Jun 17
    Reported Aug 7
    		$0.33$0.30+10.00%Beat-
    Mar 17
    Reported May 8
    		$0.39$0.38+2.63%Beat-
    Dec 16
    Reported Feb 6
    		$0.43$0.40+7.50%Beat-

    Key Metrics

    Valuation
    P/E Ratio24.22EV/EBITDA26.47x
    Price/FCF18.90xFCF Yield5.29%
    Profitability
    Profit Margin7.12%Operating Margin17.90%
    ROE11.20%ROIC4.79%
    Financial Health
    Debt/Equity1.40xInterest CoverageN/A
    Current Ratio3.08xQuick Ratio1.91x
    Trading Statistics
    Beta0.61Avg Volume724.99K
    52-Week High$123.7752-Week Low$48.98

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$113.90
    SMA 20$110.20
    SMA 50$104.51
    SMA 200$76.58
    EMA 10$116.01
    EMA 20$111.84
    EMA 50$103.69
    EMA 200$82.84

    MACD

    Line: 4.88Signal: 3.46Hist: 1.42

    ADX

    ADX: 35.0+DI: 34.2-DI: 12.4

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down4.0
    PSAR$106.76

    Bollinger Bands

    Upper Band$124.79
    Lower Band$95.62
    %B Position2647%(Upper)
    Band Width0.88

    RSI (14-Day)

    Overbought
    74.9

    Momentum Oscillators

    Stoch %K89.4
    Stoch %D91.5
    Williams %R-10.8
    ROC (10d)16.3%
    Momentum16.98
    CCI (20d)118.2
    MFI (14d)63.2

    Volatility Measures

    ATR (14d)$3.75(3.1%)
    StdDev (20d)7.29
    Hist Vol64.6%(High)

    Volume Flow

    VWAP$120.82
    OBV11.6M
    AD Line-8.1M
    CMF (20d)-0.011

    Volume Metrics

    Avg Vol (20d)740.4K
    Vol Ratio1.0x
    VWMA (20d)$112.74

    Pivot Points

    R3$125.56
    R2$124.04
    R1$122.58
    Pivot Point$121.06
    S1$119.60
    S2$118.08
    S3$116.62

    Advanced Oscillators

    TSI42.50
    Ultimate Osc68.3
    KST81.97

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$339.38M$346.35M$338.97M$327.31M$321.39M$330.60M$348.54M$345.51M$336.17M$343.29M$336.25M$318.18M
    Cost of Revenue$136.58M$148.14M$136.58M$132.57M$129.15M$137.55M$155.00M$158.07M$161.25M$167.38M$158.38M$147.67M
    Gross Profit$202.80M$198.21M$202.39M$194.74M$192.24M$193.05M$193.55M$187.44M$174.92M$175.91M$177.87M$170.51M
    Operating Expenses$145.34M$221.24M$134.99M$136.25M$138.37M$121.72M$134.52M$135.74M$135.17M$145.96M$131.89M$135.21M
    R&D$16.20M$14.45M$14.19M$14.87M$16.26M$18.30M$15.83M$14.14M$14.45M$15.86M$13.27M$12.66M
    SG&A$118.94M$120.93M$109.15M$101.61M$110.72M$115.14M$106.46M$106.95M$108.25M$109.26M$111.71M$115.32M
    Operating Income$57.46M$-23,025,000$67.40M$58.49M$53.87M$71.33M$59.03M$51.70M$39.76M$29.94M$45.98M$35.30M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$9.88M$5.37M$7.42M$7.21M$8.70M$598,000$9.11M$6.99M$0$6.53M$1.95M$2.47M
    Income Before Tax$47.57M$-28,399,000$59.98M$51.28M$45.17M$70.74M$49.92M$44.70M$46.71M$23.41M$44.03M$32.83M
    Income Tax Expense$14.56M$-8,252,000$15.23M$12.60M$11.14M$12.76M$12.42M$10.87M$8.34M$3.05M$12.79M$7.92M
    Net Income$33.01M$-20,147,000$44.74M$38.68M$34.03M$57.98M$37.49M$33.83M$38.37M$20.37M$31.24M$24.91M
    EBITDA$74.69M$-1,080,000$88.68M$81.59M$76.36M$101.58M$82.28M$77.66M$81.09M$54.40M$67.56M$55.84M
    EBIT$47.57M$-28,399,000$59.98M$51.28M$45.17M$70.74M$49.92M$44.70M$46.71M$23.41M$44.03M$32.83M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about HAE

    Government Contracts

    Gov Obligations (TTM)
    $511487
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    18
    New Awards (TTM)
    8
    Avg Remaining Term
    12.6 mo

    Top agency: Department of Defense at 56.3% of trailing twelve month obligations across 4 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    80NSSC26P0484National Aeronautics and Space AdministrationNational Aeronautics and Space Administration$131896Jul 1, 2026
    HT001426PE058Department of DefenseDefense Health Agency$87900Feb 12, 2026
    W81K0225PA048Department of DefenseDefense Health Agency$81976Aug 12, 2025
    36C10X26K0087Department of Veterans AffairsDepartment of Veterans Affairs$49692Feb 1, 2026
    HT001425PE012Department of DefenseDefense Health Agency$39282Aug 8, 2025
    36C10X26K0224Department of Veterans AffairsDepartment of Veterans Affairs$22600Apr 1, 2026
    N3239825P0714Department of DefenseDepartment of the Navy$17754Sep 30, 2025
    HT940626PE004Department of DefenseDefense Health Agency$6065Nov 10, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Haemonetics Gains 149.3% in a Year: What's Driving the Rally?

    Haemonetics (HAE) shares have surged 149.3% over the past year, driven by strong demand in its Plasma franchise and growth in its MedSurg business. The company's fiscal first-quarter 2027 revenues showed significant...

    Yahoo Finance•10/16/26•Bullish

    Mizuho lifts target for Haemonetics stock to USD 140.00 with 15.57 percent upside opportunity

    Mizuho analyst Anthony Petrone raised the price target for Haemonetics (HAE) stock to USD 140.00 from USD 95.00...

    ad-hoc-news.de•10/15/26•Bullish

    Mizuho lifts target for Haemonetics stock to USD 140.00 with 15.57 percent upside opportunity

    Mizuho analyst Anthony Petrone has raised the price target for Haemonetics (HAE) stock to USD 140.00 from USD 95.00...

    ad-hoc-news.de•10/15/26•Bullish

    Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?

    Haemonetics (HAE) is poised for growth due to its impressive MedSurg business and the robust uptake of its NexSys PCS system. Despite competitive pressures and unfavorable foreign exchange impacting operations...

    TradingView•10/15/26•Somewhat-Bullish

    Haemonetics Corporation (HAE) Stock Forecasts

    The article provides a title related to stock forecasts for Haemonetics Corporation (HAE) but the main content indicates an error in data retrieval. The page largely consists of navigation links, market data...

    Yahoo! Finance Canada•10/15/26•Neutral

    HAE Valuation and Fair Value

    P/E
    24.2x
    Forward P/E
    20.3x
    EV/EBITDA
    26.5x
    P/FCF
    18.9x
    PEG
    1.7x
    P/B
    6.6x
    See GNG's fair value

    HAE Profitability: Margins, ROIC and FCF

    Gross margin
    59.0%
    Operating margin
    17.9%
    Net margin
    7.1%
    ROIC
    4.8%
    ROE
    11.2%
    FCF margin
    21.5%
    FCF yield
    5.3%

    HAE Competitors

    CompanyTicker
    Kodiak Sciences IncKOD
    CG Oncology, Inc. Common stockCGON
    Immunovant IncIMVT
    Doximity IncDOCS
    Ligand Pharmaceuticals IncorporatedLGND
    RadNet IncRDNT
    Rhythm Pharmaceuticals IncRYTM
    Stevanato Group SpASTVN

    Sector: Healthcare

    HAE Analyst Ratings

    Consensus
    Buy
    Analysts
    11
    Strong Buy
    4
    Buy
    5
    Hold
    2
    Sell
    0
    Strong Sell
    0

    HAE Bull Case vs Bear Case

    Bull case

    • HAE converts 21.5% of revenue into free cash flow.
    • HAE beat EPS estimates in 100.0% of its last 8 reported quarters.
    • 81.8% of HAE's analyst ratings are Buy or Strong Buy.

    HAE Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    5.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $1.29
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    6 up, 3 down

    Frequently Asked Questions About HAE

    Does HAE pay dividends?

    Haemonetics Corporation (HAE) does not currently pay a regular dividend.

    What is HAE's P/E ratio?

    Haemonetics Corporation has a price-to-earnings (P/E) ratio of 24.22.

    What is HAE's market cap?

    Haemonetics Corporation (HAE) has a market capitalization of $5.51B with a current stock price of $121.35.

    Related stocks

    Sector: Healthcare

    All stocks starting with H

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In